Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Differential actions of follistatin and follistatin-like 3.

Schneyer A, Sidis Y, Xia Y, Saito S, del Re E, Lin HY, Keutmann H.

Mol Cell Endocrinol. 2004 Oct 15;225(1-2):25-8. Review.

PMID:
15451564
2.

Identification of NF-kappaB responsive elements in follistatin related gene (FLRG) promoter.

Bartholin L, Guindon S, Martel S, Corbo L, Rimokh R.

Gene. 2007 May 15;393(1-2):153-62. Epub 2007 Mar 1.

PMID:
17395406
3.

Overexpression of follistatin-like 3 in gonads causes defects in gonadal development and function in transgenic mice.

Xia Y, Sidis Y, Schneyer A.

Mol Endocrinol. 2004 Apr;18(4):979-94. Epub 2004 Jan 22.

PMID:
14739256
4.

Heparin and activin-binding determinants in follistatin and FSTL3.

Sidis Y, Schneyer AL, Keutmann HT.

Endocrinology. 2005 Jan;146(1):130-6. Epub 2004 Oct 7.

PMID:
15471966
5.

Follistatin-related protein (FSRP): a new member of the follistatin gene family.

Schneyer A, Tortoriello D, Sidis Y, Keutmann H, Matsuzaki T, Holmes W.

Mol Cell Endocrinol. 2001 Jun 30;180(1-2):33-8. Review.

PMID:
11451569
6.

Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin.

Sidis Y, Tortoriello DV, Holmes WE, Pan Y, Keutmann HT, Schneyer AL.

Endocrinology. 2002 May;143(5):1613-24.

PMID:
11956142
7.

The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.

Stamler R, Keutmann HT, Sidis Y, Kattamuri C, Schneyer A, Thompson TB.

J Biol Chem. 2008 Nov 21;283(47):32831-8. doi: 10.1074/jbc.M801266200. Epub 2008 Sep 2.

8.

Genomic organization and promoter analysis of mouse follistatin-related gene (FLRG).

Nakatani M, Yamakawa N, Matsuzaki T, Shimasaki S, Sugino H, Tsuchida K.

Mol Cell Endocrinol. 2002 Mar 28;189(1-2):117-23.

PMID:
12039070
9.

Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.

Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A.

Endocrinology. 2006 Jul;147(7):3586-97. Epub 2006 Apr 20.

PMID:
16627583
10.

Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin.

Bilezikjian LM, Blount AL, Leal AM, Donaldson CJ, Fischer WH, Vale WW.

Mol Cell Endocrinol. 2004 Oct 15;225(1-2):29-36. Review.

PMID:
15451565
11.

Differential biosynthesis and intracellular transport of follistatin isoforms and follistatin-like-3.

Saito S, Sidis Y, Mukherjee A, Xia Y, Schneyer A.

Endocrinology. 2005 Dec;146(12):5052-62. Epub 2005 Sep 8.

PMID:
16150905
12.

Novel factors in regulation of activin signaling.

Tsuchida K, Nakatani M, Matsuzaki T, Yamakawa N, Liu Z, Bao Y, Arai KY, Murakami T, Takehara Y, Kurisaki A, Sugino H.

Mol Cell Endocrinol. 2004 Oct 15;225(1-2):1-8.

PMID:
15451561
13.

FLRG, member of the follistatin family, a new player in hematopoiesis.

Maguer-Satta V, Rimokh R.

Mol Cell Endocrinol. 2004 Oct 15;225(1-2):109-18. Review.

PMID:
15451575
14.

A novel role for fibronectin type I domain in the regulation of human hematopoietic cell adhesiveness through binding to follistatin domains of FLRG and follistatin.

Maguer-Satta V, Forissier S, Bartholin L, Martel S, Jeanpierre S, Bachelard E, Rimokh R.

Exp Cell Res. 2006 Feb 15;312(4):434-42. Epub 2005 Dec 5.

PMID:
16336961
15.

Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG).

Schneyer A, Schoen A, Quigg A, Sidis Y.

Endocrinology. 2003 May;144(5):1671-4.

PMID:
12697670
16.

Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis.

Brown ML, Bonomi L, Ungerleider N, Zina J, Kimura F, Mukherjee A, Sidis Y, Schneyer A.

Obesity (Silver Spring). 2011 Oct;19(10):1940-9. doi: 10.1038/oby.2011.97. Epub 2011 May 5.

17.
18.

Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.

Cash JN, Angerman EB, Keutmann HT, Thompson TB.

Mol Endocrinol. 2012 Jul;26(7):1167-78. doi: 10.1210/me.2012-1061. Epub 2012 May 16.

19.

The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum.

Hill JJ, Davies MV, Pearson AA, Wang JH, Hewick RM, Wolfman NM, Qiu Y.

J Biol Chem. 2002 Oct 25;277(43):40735-41. Epub 2002 Aug 22.

20.

Follistatin-like 3 (FSTL3) mediated silencing of transforming growth factor β (TGFβ) signaling is essential for testicular aging and regulating testis size.

Oldknow KJ, Seebacher J, Goswami T, Villen J, Pitsillides AA, O'Shaughnessy PJ, Gygi SP, Schneyer AL, Mukherjee A.

Endocrinology. 2013 Mar;154(3):1310-20. doi: 10.1210/en.2012-1886. Epub 2013 Feb 13.

Supplemental Content

Support Center